| | | TOP STORY |
Brittle-Bone Babies Helped by Fetal Stem Cell Grafts
Osteogeneis imperfecta is a congenital bone disease that causes stunted growth and repeated, painful fracturing. Ultrasound scans can reveal fractures already in the fetus, and now an international team of researchers from Sweden, Singapore and Taiwan have treated two babies in utero by injecting bone-forming stem cells. [Press release from the Karolinska Institutet discussing online prepublication in Stem Cells Translational Medicine]
Press Release |
Abstract
|
|
| |
| REVIEWS |
Neural Stem Cell Therapies for Enteric Nervous System Disorders
The authors discuss diseases that might be targets for stem cell therapies and the barriers that could limit treatment application. They explore various sources of stem cells and the proof of concept for their use. [Nat Rev Gastroenterol Hepatol]
Abstract
Ischemic Preconditioning for Cell-Based Therapy and Tissue Engineering
The non-genetic approach of ischemic/hypoxic preconditioning to enhance cell- and tissue-based therapies has received much attention in recent years due to its non-invasive drug-free application. The authors discuss the current development of hypoxic/ischemic preconditioning to enhance stem cell-based cardiac repair and regeneration. [Pharmacol Ther]
Abstract
Visit our reviews page to see a complete list of reviews in the cell, gene and immunotherapy research field.
|
| | | BUSINESS |
Medimmune and The Johns Hopkins University Announce Five-Year, $6.5 Million Collaboration to Drive Medical Research and Discovery
MedImmune, AstraZeneca’s global biologics research and development arm, and The Johns Hopkins University announced they have entered into a five-year, $6.5 million research collaboration. The joint research projects will focus on MedImmune’s therapeutic areas of interest, including cardiovascular and metabolic disease; oncology; respiratory, inflammation and autoimmunity; infectious disease and neuroscience. [MedImmune, LLC]
Press Release
Stem Cell Agency Board Funds More than $61 Million in Cancer, Sickle Cell Disease and Vision Loss and Sets New Focus
Reflecting the progress being made in moving the most promising therapies out of the lab and into clinical trials, the state stem cell agency, the California Institute for Regenerative Medicine, voted to approve $61 million in funding for its third round of Disease Team awards. This round of awards targets diseases like leukemia and other solid tumor cancers – such as breast and prostate – that have not responded to conventional treatment. [California Institute for Regenerative Medicine]
Press Release
Stem Cell Agency Funds UC Davis Tissue-Engineering Research
A University of Califronia (UC) Davis team has received a $4.4 million grant from the California Institute for Regenerative Medicine to develop a stem cell-derived airway transplant to cure a difficult, life-threatening problem known as severe airway stenosis. [UC Davis Medical Center]
Press Release
BrainStorm Receives $800,000 Non-Dilutive Grant from Israel’s Office of the Chief Scientist
BrainStorm Cell Therapeutics Inc. announced that it was awarded an $800,000 non-dilutive grant from Israel’s Office of the Chief Scientist for the year 2014. The grant is intended to support BrainStorm’s clinical and product development for its stem cell therapy candidate NurOwn™. [BrainStorm Cell Therapeutics Inc.]
Press Release
Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer
Cellular Biomedicine Group, Inc. announced that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of tumor stem cell specific dendritic cell therapy for hepatocellular carcinoma, the most common type of liver cancer. [Cellular Biomedicine Group, Inc.]
Press Release
UTHealth Researchers Study Stem Cell Treatments for Children with CP
A first-of-its-kind clinical trial studying two forms of stem cell treatments for children with cerebral palsy (CP) has begun at The University of Texas Health Science Center at Houston (UTHealth) Medical School. The double-blinded, placebo-controlled study’s purpose includes comparing the safety and effectiveness of banked cord blood to bone marrow stem cells. [The University of Texas Health Science Center at Houston]
Press Release
Researchers Evaluating Immunotherapy Approaches for Treating Metastatic Kidney, Prostate, Bladder Cancers
Researchers at the Roswell Park Cancer Institute Center for Immunotherapy are enrolling patients in three different clinical trials of novel immunotherapy approaches for treating genitourinary cancers. [Roswell Park Cancer Institute]
Press Release
Fibrocell Science Chairman & CEO David Pernock Joins Board
Fibrocell Science, Inc. announced Chairman and CEO David Pernock has joined the board of the Alliance for Regenerative Medicine, a global advocacy organization whose diverse membership represents leading regenerative medicine companies and investors, university-based and non-profit research institutions, patient advocacy groups, pharmaceutical companies engaged in regenerative medicine research, and other organizations supporting regenerative medicine. [Fibrocell Science, Inc.]
Press Release
|
|
